Layilin Antibody (OTI4D3)
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-45613
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI4D3
Concentration
1 mg/ml
Product Specifications
Immunogen
Full length human recombinant protein of human LAYN(NP_849156) produced in HEK293T cell.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Theoretical MW
42.1 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Scientific Data Images for Layilin Antibody (OTI4D3)
Western Blot: Layilin Antibody (OTI4D3) [NBP2-45613]
Western Blot: Layilin Antibody (4D3) [NBP2-45613] - Analysis of HEK293T cells were transfected with the pCMV6-ENTRY control (Left lane) or pCMV6-ENTRY Layilin.Applications for Layilin Antibody (OTI4D3)
Application
Recommended Usage
Western Blot
1:2000
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS (pH 7.3), 1.0% BSA and 50% Glycerol
Preservative
0.02% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20C. Avoid freeze-thaw cycles.
Background: Layilin
Alternate Names
LAYN, LYAN
Gene Symbol
LAYN
Additional Layilin Products
Product Documents for Layilin Antibody (OTI4D3)
Product Specific Notices for Layilin Antibody (OTI4D3)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...